Brought to you by 
MorphoSys and Merck Serono team up to develop immune checkpoint inhibitors for cancer
02 Feb 2023
Executive Summary
Therapeutic antibody firm MorphoSys AG will use its Ylanthia fragment antigen-binding (Fab) library to identify antibodies against immune checkpoints for Merck KGAA’s Merck Serono SA.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MorphoSys and Merck Serono team up to develop immune checkpoint inhibitors for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice